Evidence map›Paper›PMID 41152783›Full record

ArticleBMC infectious diseases2025

Viral hepatitis B co-infection among people living with HIV: a National cross-sectional survey in Togo in 2023.

Roméo Mèdéssè Togan, Frédéric Iman Youa, Rogatien Comlan Atoun, Malanna Bigma, Rodion Yao Konu, Arnold Junior Sadio, Martin Kouame Tchankoni, Alassane Ouro Medeli, Oumarou I Wone Adama, Palokinam Pitche and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Roméo Mèdéssè ToganFaculty of Health Sciences, Department of Public Health, University of Lomé, Lomé, Togo.
Frédéric Iman YouaFaculty of Health Sciences, Department of Public Health, University of Lomé, Lomé, Togo.
Rogatien Comlan AtounFaculty of Health Sciences, Department of Public Health, University of Lomé, Lomé, Togo.
Malanna BigmaFaculty of Health Sciences, Department of Public Health, University of Lomé, Lomé, Togo.
Rodion Yao KonuFaculty of Health Sciences, Department of Public Health, University of Lomé, Lomé, Togo.
Arnold Junior SadioTraining and Research Center in Public Health (CRFSP), University of Lomé, Lomé, Togo.
Martin Kouame TchankoniTraining and Research Center in Public Health (CRFSP), University of Lomé, Lomé, Togo.
Alassane Ouro MedeliLaboratory of Molecular Biology and Immunology, University of Lomé, Lomé, Togo.
Oumarou I Wone AdamaAfrican Center for Research in Epidemiology and Public Health (CARESP), Lomé, Togo.
Palokinam PitcheDepartment of Dermatology, University Teaching Hospital of Lomé, Lomé, Togo.
Gilles WandelerDepartment of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland.
Didier Koumavi EkoueviFaculty of Health Sciences, Department of Public Health, University of Lomé, Lomé, Togo. didier.ekouevi@gmail.com.
Claver Anoumou DagnraLaboratory of Molecular Biology and Immunology, University of Lomé, Lomé, Togo.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextHIV/HBV co-infection accelerates the progression of chronic hepatitis towards end-stage liver disease. In Togo, little is known about the prevalence of hepatitis B in people living with HIV (PLWH). The objective of this study was to estimate the determinants of hepatitis B virus (HBV) infection among PLWH in Togo in 2023.

methodsA cross-sectional study was carried out between May and October 2023 among PLWH receiving antiretroviral treatment in HIV care centers in the six health regions of Togo. Serological tests were used for the detection of HBV surface antigen (HBsAg), anti-HBs antibody, and total anti-HBc antibody. The HBV DNA viral load was measured in HBsAg positive PLWH. Logistic regression analyses were performed to assess associated factors with HIV/HBV co-infection.

resultsA total of 897 PLWH (74.9% women) were included. The median age was 45 years (IQR: 38-53). The prevalence of viral hepatitis B was 6.5%, 95% CI [5.0 - 8.3]. This prevalence was higher in northern Togo (12.0%) than in southern Togo (5.2%) (OR: 2,7 IC 95% 1,44 - 4,98). Among 58 HBsAg+ PLWH, 93% had an undetectable HBV viral load (<10IU/ml) on Tenofovir/Lamivudine/Dolutegravir. Among HBsAg-negative PLWH (n=100), 2% were vaccinated against HBV, 61% had been exposed to HBV and 37% were not protected against HBV.

conclusionHBV prevalence is high among PLWH, especially in northern Togo, and the HBV viral load is suppressed in almost all patients on ART treatment. One third of our study population was susceptible to HBV infection, and in urgent need of HBV vaccination.

Indexed as

CoinfectionHepatitis BHIV InfectionsAdultCross-Sectional StudiesFemaleHepatitis B AntibodiesHepatitis B Surface AntigensHepatitis B virusHumansMaleMiddle AgedPrevalenceTogoViral LoadHepatitis B AntibodiesHepatitis B Surface AntigensHIVPrevalenceTogoViral hepatitis B

Identifiers

PMID41152783
PMCPMC12570555

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.